CooperCompanies, US21664P1039

CooperCompanies stock holds firm after June quarter beat

Published on 08/27/2026 at 21:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CooperCompanies stock is digesting June 4, 2026 results, with $1.08 billion in revenue, $1.21 in EPS and FY 2026 guidance of $4.58 to $4.66 per share.

Draufsicht-Flatlay auf Marmor mit Aktienzertifikat, ISIN-Karte, Kontaktlinsenbehälter und Stethoskop
CooperCompanies Flatlay US21664P1039 mit Aktienzertifikat ISIN-Karte Kontaktlinsenbehälter Stethoskop Pinzette und medizinischen Laborutensilien, Illustration mit AI erstellt.

CooperCompanies (US21664P1039) is trading around $72.68, with a $14.17 billion market value and a 52-week range of $58.89 to $89.83 as of August 27, 2026. The medical device group also posted June 4, 2026 quarter revenue of $1.08 billion and earnings of $1.21 per share, both above the $1.05 billion and $1.10 estimates in the same earnings snapshot.

June quarter still sets the tone

The latest quarterly comparison is straightforward: revenue rose 7.9% year over year, while EPS improved from $0.96 a year earlier to $1.21. That mix matters because the market is still pricing a company whose FY 2026 guidance sits at $4.58 to $4.66 a share, with analysts at $4.63 for the year.

For investors, the gap between the reported quarter and the full-year range is small enough to keep execution front and center. A quarter at $1.21 EPS and a consensus of $4.63 for FY 2026 leaves little room for a clear slowdown.

Valuation does the talking

At 61.59 times earnings, the stock still carries a premium multiple against a 0.83 beta. The current setup suggests the shares are being judged less on a single quarter and more on whether Cooper can keep converting that $1.08 billion revenue base into steady margin support.

The stock's 52-week band from $58.89 to $89.83 gives a useful reference point for the current $72.68 level. That leaves the shares between the low and high, with the market cap at $14.17 billion anchoring the valuation discussion.

Contact lenses and diagnostics

Cooper's two main businesses remain contact lenses and fertility and womens' health diagnostics, with brands such as CooperVision and CooperSurgical carrying the operating story. Those product lines matter because the reported June quarter beat came from a business that still relies on recurring demand rather than one-off demand spikes.

Price and setup

As of August 27, 2026, CooperCompanies trades at $72.68, and the market has it positioned closer to the midpoint of its 52-week band than to either extreme.

Company facts

Company: The Cooper Companies, Inc.

ISIN: US21664P1039

Ticker: COO

Exchange: Nasdaq

Sector / Industry: Health Care / Medical Instruments & Supplies

Index membership: S&P 500

Price (as of August 27, 2026): $72.68 USD

Market cap: $14.17 billion

Next earnings date: September 9, 2026

Disclaimer...

en | US21664P1039 | COOPERCOMPANIES | boerse | 70010617 | bgmi